Ask AI
ProCE Banner Activity

FAQs: Targeting BCMA in Early Relapsed/Refractory Myeloma

Clinical Thought

In this commentary, experts address questions on what oncology pharmacists need to know now and in the near future regarding targeting BCMA in multiple myeloma after patients have received 1 or 2 previous lines of therapy.

Released: June 26, 2026

Share

Provided by

Provided by ProCE, LLC.

ProCE Banner

Supporters

Supported by an educational grant from GSK.

GSK

Target Audience

This activity has been designed to meet the educational needs of oncology pharmacists and other healthcare professionals caring for patients with relapsed/refractory multiple myeloma. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Explain the rationale for targeting BCMA to improve outcomes in patients with early R/R MM

  • Summarize recent updates on BCMA-targeted therapies for R/R MM in treatment discussions with physicians and patients

  • Employ evidence-based strategies to monitor and manage ocular toxicity associated with BCMA-targeted antibody–drug conjugates for early R/R MM in collaboration with the multidisciplinary care team

Financial Disclosures

Primary Author

Donald Moore, PharmD, BCPS, BCOP, DPLA, FCCP, FASHP: consultant/advisor/speaker: Genentech, Genmab, GSK, Incyte, Johnson & Johnson, Lilly, Sanofi.

Anthony Perissinotti, PharmD, BCOP: consultant/advisor/speaker: Amgen, Jazz, Servier.